Accelerating Novel, NextGen Immunomodulators for Patients in Need
Our algorithms are custom built for the problem we are trying to solve, and the combination of datasets we use are unique in breadth and quality. We have overcome the scarcity of data for rare diseases by creating high-quality datasets from our own experiments, modeling physics-based simulations, and by curating publicly available datasets using proprietary methods. We integrate wet lab, bioinformatics, and computational physics to realize greater predictive power in our end-to-end platform. Unlike algorithms built solely on data, ours are built to leverage the scientific expertise at GEn1E enabling us to overcome the high barriers in the pharmaceuticals industry. We are also hyper-focused on two targets (p38ɑ/MK2 & ERK1/2) that are involved in multiple pulmonary, oncology, auto-immune, neurological, and muscle degenerative diseases. The intersection of our “platform-in-a-mechanism” model and end-to-end platform will bring novel therapies to millions of patients faster and cheaper with a high probability of success. We are cementing the foundation for the next generation of techbio companies that will accelerate therapies with groundbreaking capital efficiency in this challenging macroeconomic environment.
Out of 7000 known rare diseases, 95%+ have no approved or effective treatments, affecting 30 million people in the US alone (or 1 in 10 people). For patients and their families, the lack of therapies means that in addition to the devastating effects of the disease there is a greater financial burden due to longer stays in the ICU/hospitals, frequent medical visits, and higher readmission rates. The cost to society is high as well; acute respiratory distress syndrome, our first indication, costs $20 Billion to society in the US alone, has no FDA approved therapeutic treatment, and a 40% mortality rate. With G.R.I.D, we are disrupting the traditional drug development paradigm with active learning that accelerates the development of our selective next-generation immunomodulators, enabling us to achieve a greater probability of success and bring therapies to patients with huge unmet medical needs.
Our lead compound, a novel nextgen treatment for ARDS, has successfully completed a Phase I study (single ascending dose/multiple ascending dose) in 48 people in New Zealand. We have also completed animal models for Pneumonia and Influenza. In both cases, the data is speaking for itself. Pre-clinical animal models showed a 4-5X increase in survival. We have also built a pipeline of 21+ novel immunomodulators with the lead being Phase 2 ready and 3 in the lead optimization stage. All of this was accomplished in less than 3 years using only $5M seed funding—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in our industry.
